Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 12/20 | 0.34 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.32 |
| ▸ | BID | P55957 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592260 | 0.91 | UTS2R (0.36) | UTS2RBCL2A1BIDCYP2C9CYP2C19 | |
| SCHEMBL4592262 | 0.91 | UTS2R (0.36) | UTS2RBCL2A1BIDCYP2C9CYP2C19 | |
| SCHEMBL4592817 | 0.91 | UTS2R (0.38) | UTS2RBCL2A1BID | |
| SCHEMBL4592820 | 0.91 | UTS2R (0.38) | UTS2RBCL2A1BID | |
| SCHEMBL9982664 | 0.90 | PDK2 (0.34) | UTS2R | |
| SCHEMBL4592462 | 0.89 | UTS2R (0.37) | UTS2RBCL2A1BID | |
| SCHEMBL4592463 | 0.89 | UTS2R (0.37) | UTS2RBCL2A1BID | |
| SCHEMBL4592583 | 0.85 | ALDH1A1 (0.40) | ADRB1 | |
| SCHEMBL4592582 | 0.85 | ALDH1A1 (0.40) | ADRB1 | |
| SCHEMBL4592695 | 0.85 | UTS2R (0.35) | UTS2RBCL2A1BID |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071810-B2 | 3-(3-Amino-2,6-diisopropyl-phenyl)-1-(4-isopropyl-phenyl)-1-(4-methoxy-benzyl)-urea; autoimmune disorders; inflammation | JERINI AG (DE) | 2011-12-06 | — | — | US | claimed |
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | claimed |
| EP-1885691-A1 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2008-02-13 | — | — | EP | claimed |
| WO-2006128670-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-12-07 | — | — | WO | claimed |
| US-8071810-B2 | 3-(3-Amino-2,6-diisopropyl-phenyl)-1-(4-isopropyl-phenyl)-1-(4-methoxy-benzyl)-urea; autoimmune disorders; inflammation | JERINI AG (DE) | 2011-12-06 | — | — | US | disclosed |
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1885691-A1 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006128670-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080220003-A1 | C5a Receptor Antagonists | C3AR1, C5AR2, C5AR1 | UTS2R 206/4885BCL2A1 4036/4885BID 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.